China-based Leman Biotech has closed a Series A extension financing round raising nearly RMB 200 million (USD 29 million). The round was co-led by Yuecai Zhongyin Private Equity and XtalPi, with participation from other institutional and individual investors. Founded in 2021, Leman is a clinical-stage biotech focused on developing next-generation immunometabolic cell therapies, with a pipeline spanning haematological malignancies, solid tumours, and autoimmune diseases. The funds will be used to advance a registrational Phase I trial for its ultra-low-dose metabolic-enhanced CD19 CAR-T therapy and to accelerate automated manufacturing process development.

Leman's core technology is its META 10 platform, an IL-10-mediated immunometabolic reprogramming technology designed to address T-cell exhaustion. The company's lead CAR-T candidate has shown promising complete response rate (CRR) in a small investigator-initiated trial for lymphoma and leukaemia at doses 1000 times lower than conventional therapies. In systemic lupus erythematosus (SLE), the same candidate has demonstrated remission without the need for lymphodepletion. The company has also initiated a trial for a metabolic-enhanced tumour-infiltrating lymphocyte (TIL) therapy for solid tumours and is advancing multiple investigational new drug applications (NDAs) in both China and the US.

PharmCube's NextBiopharm® database shows that Leman's portfolio covers a range of innovative drug modalities. Click here to request a free trial for NextBiopharm®.